Max Robotics — Global Service Robot Directory + US Certification

About

Mitch Humphreys is a leading urologic surgeon and researcher whose work has fundamentally advanced the surgical treatment of benign prostatic hyperplasia (BPH), particularly for patients with large prostates. His primary research focus is the development and clinical validation of Aquablation therapy, a minimally invasive, water-jet-based procedure for treating lower urinary tract symptoms (LUTS) due to BPH. Humphreys’ major contributions include leading the landmark WATER II clinical trial, which demonstrated the long-term safety and efficacy of Aquablation in prostates sized 80-150 cc—a population traditionally requiring more invasive open surgery. His 2019 paper on 1-year results from this trial has garnered 63 citations, while the recently published 5-year outcomes (49 citations) provide definitive evidence of durable symptom relief and low retreatment rates. He has also conducted comparative analyses between the WATER and WATER II trials (25 citations) and performed a comprehensive meta-analysis of functional outcomes across diverse prostate anatomies (14 citations). Through this body of work, Humphreys has established Aquablation as a standardized, reproducible alternative to simple prostatectomy, offering patients with large prostates a safer, less morbid surgical option.